Pre-IPO Sichuan Biokin Pharmaceutical - Would Investors Be Willing to Take a Gamble?

112 Views04 Oct 2024 08:55
​Biokin's future hinges on collaboration with BMS for BL-B01D1, as traditional business shrink due to VBP/fierce competition.Overvaluation poses risk of valuation plummeting if BL-B01D1's R&D fail
What is covered in the Full Insight:
  • Introduction to Sichuan Biokin Pharmaceutical
  • Current Revenue Streams and Challenges
  • Transformative Collaboration with BMS
  • Clinical Trials and Market Potential of BL-B01D1
  • Valuation Concerns and Market Risks
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
x